Logo
x

Search

Subscribe Now

daiichi sankyo

Daiichi Sankyo’s Datroway Receives the MHLW’s Approval for Unresectable or Recurrent HR+/HER2- Breast Cancer

Daiichi Sankyo’s Datroway Receives the MHLW’s Approval for Unresectable or Recurrent HR+/HER2- Breast Cancer

  • December 27, 2024
Daiichi Sankyo Begins the P-III (QuANTUM-Wild) Study of Vanflyta (Quizartinib) to Treat FLT3-ITD Negative Acute Myeloid Leukemia (AML)

Daiichi Sankyo Begins the P-III (QuANTUM-Wild) Study of Vanflyta (Quizartinib) to Treat FLT3-ITD Negative Acute Myeloid Leukemia (...

  • December 11, 2024
Daiichi Sankyo Reports Pooled Analysis from TROPION-Lung05 & TROPION-Lung01 Trials of Datopotamab Deruxtecan (Dato-DXd) for NSCLC

Daiichi Sankyo Reports Pooled Analysis from TROPION-Lung05 & TROPION-Lung01 Trials of Datopotamab Deruxtecan (Dato-DXd) for NSCLC

  • December 6, 2024
Daiichi Sankyo Reports the sNDA Submission of Enhertu to Treat HER2 Low or Ultralow Metastatic Breast Cancer in Japan

Daiichi Sankyo Reports the sNDA Submission of Enhertu to Treat HER2 Low or Ultralow Metastatic Breast Cancer in Japan

  • October 4, 2024
Daiichi Sankyo’ Enhertu Gains the US FDA’s Breakthrough Therapy Designation to Treat HER2 Low or HER2 Ultralow Metastatic Breast Cancer

Daiichi Sankyo’ Enhertu Gains the US FDA’s Breakthrough Therapy Designation to Treat HER2 Low or HER2 Ultralow Metastatic Breast C...

  • August 20, 2024
Daiichi Reports the EMA’s Validation of Application for Enhertu to treat HER2 Low or HER2 Ultralow Metastatic Breast Cancer

Daiichi Reports the EMA’s Validation of Application for Enhertu to treat HER2 Low or HER2 Ultralow Metastatic Breast Cancer

  • August 20, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.